
CLAIMS


1. A compound of formula (I)



(I)

or a salt thereof, wherein

A represents a heteroaryl selected from the group consisting of:



R^1 represents one of the following substituents: (1) unsubstituted or substituted, preferably substituted C_1-C_7-alkyl, wherein said substituents are independently selected from one or more, preferably one to nine of the following moieties: deuterium, fluoro, or one to two of the following moieties C_3-C_5-cycloalkyl; (2) optionally substituted C_3-C_5-cycloalkyl wherein said substituents are independently selected from one or more, preferably one to four of the following moieties: deuterium, C_1-C_4-alkyl (preferably methyl), fluoro, cyano, aminocarbonyl; (3) optionally substituted phenyl wherein said substituents are independently selected from one or more, preferably one to two of the following moieties: deuterium, halo, cyano, C_1-C_7-alkyl, C_1-C_7-alkylamino, di(C_1-C_7-alkyl)amino, C_1-C_7-alkylaminocarbonyl, di(C_1-C_7-alkyl)aminocarbonyl, C_1-C_7-alkoxy; (4) optionally mono- or di- substituted amine; wherein said substituents are independently selected from the following moieties: deuterium, C_1-C_7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro, chloro, hydroxy), phenylsulfonyl (which is unsubstituted or substituted by one or more, preferably one, C_1-C_7-alkyl, C_1-C_7-alkoxy, di(C_1-C_7-alkyl)amino-C_1-C_7-alkoxy); (5) substituted sulfonyl; wherein said

substituent is selected from the following moieties: C_1-C_7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro), pyrrolidino, (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, hydroxy, oxo; particularly one oxo); (6) fluoro, chloro;


R^2 represents hydrogen;

R^3 represents (1) hydrogen, (2) fluoro, chloro, (3) optionally substituted methyl, wherein said substituents are independently selected from one or more, preferably one to three of the following moieties: deuterium, fluoro, chloro, dimethylamino;

with the exception of (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(tert-butyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide).

2. A compound according to any preceding claim, wherein

A represents a heteroaryl selected from the group consisting of:



R^1 represents: (1) cyclopropylmethyl or optionally substituted, branched C_3-C_7-alkyl, wherein said substituents are independently selected from one or more, preferably one to nine of the following moieties: deuterium, fluoro; (2) optionally substituted cyclopropyl or cyclobutyl wherein said substituents are independently selected from one or more, preferably one to four of the following moieties: methyl, deuterium, fluoro, cyano, aminocarbonyl; (3) optionally substituted phenyl wherein said substituents are independently selected from one or more, preferably one to two of the following moieties: deuterium, halo, cyano, C_1-C_7-alkyl, C_1-C_7-alkylamino, di(C_1-C_7-alkyl)amino, C_1-C_7-alkylaminocarbonyl, di(C_1-C_7-alkyl)aminocarbonyl, C_1-C_7-alkoxy; (4) optionally mono- or di- substituted amine; wherein said substituents are independently selected from the following moieties: deuterium, C_1-C_7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro, chloro, hydroxy), phenylsulfonyl (which is unsubstituted or substituted by one or more, preferably one, C_1-C_7-alkyl, C_1-C_7-

alkoxy, di(C_1-C_7-alkyl)amino-C_1-C_7-alkoxy); (5) substituted sulfonyl; wherein said substituent is selected from the following moieties: C_1-C_7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro), pyrrolidino, (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, hydroxy, oxo; particularly one oxo); (6) fluoro, chloro;


R^2 represents hydrogen;

R^3 represents hydrogen, methyl, CD_3, CH_2Cl, CH_2F, $CH_2N(CH_3)_3$;


with the exception of (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(tert-butyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide).

3. A compound according to claim 1 or claim 2, wherein

A represents a heteroaryl selected from the group consisting of:




4. A compound according to claim 1 or claim 2, wherein the compound of formula (I) is of the formula (IB)



(IB),

with the exception of (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(tert-butyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide).

5. A compound according to any one of claims 1 to 3, wherein the compound of formula (I) is of the formula (IA)



(IA).

6. A compound, in free form or in pharmaceutically acceptable salt form, selected from,
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-*tert*-butyl-pyridin-4-yl)-4-methyl-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-cyclopropyl-pyridin-4-yl)-4-methyl-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(2-fluoro-phenyl)-pyridin-4-yl]-4-methyl-thiazol-2-yl}-amide);
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-cyclobutyl-pyridin-4-yl)-4-methyl-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1-methyl-cyclopropyl)-pyridin-4-yl]-thiazol-2-yl}-amide);
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1-methyl-cyclobutyl)-pyridin-4-yl]-thiazol-2-yl}-amide);
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-*tert*-butyl-pyridin-4-yl)-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-isopropyl-pyridin-4-yl)-4-methyl-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-cyclobutyl-pyridin-4-yl)-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(1-methyl-cyclopropyl)-pyridin-4-yl]-thiazol-2-yl}-amide);
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(1-trifluoromethyl-cyclopropyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(1-trifluoromethyl-cyclobutyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1-trifluoromethyl-cyclopropyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1-trifluoromethyl-cyclobutyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(1-methyl-cyclobutyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(1-cyano-cyclopropyl)-pyridin-4-yl]-4-methyl-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(1-cyano-cyclobutyl)-pyridin-4-yl]-4-methyl-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(1-carbamoyl-cyclobutyl)-pyridin-4-yl]-4-methyl-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(2-dimethylamino-1,1-dimethyl-ethyl)-pyridin-4-yl]-4-methyl-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-diethylamino-pyridin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-diethylamino-pyridin-4-yl)-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(3-*tert*-butyl-3H-benzoimidazol-5-yl)-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(3-*tert*-butyl-2-methyl-3H-benzoimidazol-5-yl)-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(3-ethyl-3H-benzoimidazol-5-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-[(5-{2-[1-(4-methoxy-phenyl)-1-methyl-ethyl]-pyridin-4-yl}-4-methyl-thiazol-2-yl)-amide];

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-[(5-{2-[1-(4-methoxy-phenyl)-1-methyl-ethyl]-pyridin-4-yl}-thiazol-2-yl)-amide];

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-[(5-{2-[1-(4-methoxy-phenyl)-cyclopropyl]-pyridin-4-yl}-4-methyl-thiazol-2-yl)-amide];

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-[(5-{2-[1-(4-methoxy-phenyl)-cyclopropyl]-pyridin-4-yl}-thiazol-2-yl)-amide];

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-{1-[4-(3-dimethylamino-propoxy)-phenyl]-1-methyl-ethyl}-pyridin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1-d_3-methyl-cyclobutyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(1-d_3-methyl-cyclobutyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-d_3-methyl-5-[2-(1-methyl-cyclopropyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-d_3-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-dimethylaminomethyl-5-[2-(1-d_3-methyl-cyclobutyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-chloro-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-fluoromethyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(5-benzenesulfonylamino-6-chloro-pyridin-3-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(5-benzenesulfonylamino-6-chloro-pyridin-3-yl)-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(6-amino-5-trifluoromethyl-pyridin-3-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1-methyl-cyclopropyl)-pyrimidin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-isopropyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-benzyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-ethyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-methoxymethyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(2,6-dichloro-benzyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-isobutyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(4-methoxy-phenoxymethyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(3-methoxy-phenoxymethyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(2-fluoro-phenyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-trifluoromethyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1,1,2-trimethyl-propyl)-pyrimidin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-[(5-{2-[1-(4-methoxy-phenyl)-1-methyl-ethyl]-pyrimidin-4-yl}-4-methyl-thiazol-2-yl)-amide];

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1,1-dimethyl-propyl)-pyrimidin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1-methyl-1-p-tolyl-ethyl)-pyrimidin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(1-phenyl-cyclopentyl)-pyrimidin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-cyclopropyl-pyrimidin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-cyclobutyl-pyrimidin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-d_9-tert-butyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2-methyl-cyclopropyl)-pyrimidin-4-yl]-thiazol-2-yl}-amide);

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-diethylamino-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};

(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyrimidin-4-yl]-thiazol-2-yl}-amide);
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(ethyl-methyl-amino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide);
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(6-cyclopropyl-pyrazin-2-yl)-4-methyl-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[4-methyl-5-(5-trifluoromethyl-pyridin-3-yl)-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(6-d_{10}-diethylamino-pyrazin-2-yl)-4-methyl-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(6-diethylamino-pyrazin-2-yl)-4-methyl-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-cyclopropylmethyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(2-fluoro-1,1-dimethyl-ethyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide);
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{[5-(2-tert-butyl-6-methyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide};
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(2-fluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-4-methyl-thiazol-2-yl}-amide);
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(2-fluoro-1-fluoromethyl-1-methyl-ethyl)-pyridin-4-yl]-4-methyl-thiazol-2-yl}-amide.

7. A compound of the formula (I) according to any one of claims 1 to 6, in free form or in pharmaceutically acceptable salt form, for use as a pharmaceutical.

8. A compound of the formula (I) according to any one of claims 1 to 6, in free form or in pharmaceutically acceptable salt form, for use in the treatment of one or more phosphatidylinositol 3-kinase (PI3K) mediated diseases.

9. Use of a compound of formula (I) according to any one of claims 1 to 6, in free form or in pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment of one or more phosphatidylinositol 3-kinase (PI3K) mediated diseases.

10. A method of treatment of a phosphatidylinositol 3-kinase (PI3K) mediated disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 6, in free form or in pharmaceutically acceptable salt form.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 6, in free form or in pharmaceutically acceptable salt formand one or more pharmaceutically acceptable.

12. A combined pharmaceutical composition, adapted for simultaneous or sequential administration, comprising a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 6 in free form or in pharmaceutically acceptable salt form and a therapeutically effective amount of one or more combination partners; and one or more pharmaceutically acceptable excepients.

13. A pharmaceutical composition according to claim 11 or a combined pharmaceutical composition according to claim 12 for use in the treatment of a Protein tyrosine kinase mediated disease, in particular a phosphatidylinositol 3-kinase (PI3K) mediated disease.


14. A compound for use according to claim 8, use of a compound according to claim 9, or a method of treatment according to claim 10, wherein said phosphatidylinositol 3-kinase (PI3K) mediated disease is a PI3K alpha mediated disease.

15. A compound for use according to claim 8, use of a compound according to claim 9, or a method of treatment according to claim 10, wherein said phosphatidylinositol 3-kinase (PI3K) mediated disease is dependent on overexpression or amplification of PI3K alpha, somatic mutation of PIK3CA or germline mutations or somatic mutation of PTEN or mutations and translocation of p85α that serve to up-regulate the p85-p110 complex.

16. A compound according to any of one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disease; a benign or malignant tumor; a cancer selected from sarcoma; lung; bronchus; prostate; breast


(including sporadic breast cancers and sufferers of Cowden disease); pancreas; gastrointestinal cancer; colon; rectum; colon carcinoma; colorectal adenoma; thyroid; liver; intrahepatic bile duct; hepatocellular; adrenal gland; stomach; gastric; glioma; glioblastoma; endometrial; melanoma; kidney; renal pelvis; urinary bladder; uterine corpus; uterine cervix; vagina; ovary; multiple myeloma; esophagus; a leukaemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; a carcinoma of the brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma; melanoma; villous colon adenoma; a neoplasia; a neoplasia of epithelial character; lymphomas; a mammary carcinoma; basal cell carcinoma; squamous cell carcinoma; actinic keratosis; tumor diseases, including solid tumors; a tumor of the neck or head; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Walden stroem disease.

17. A process for the manufacture of a compound of the formula (I) according to any one of claims 1 to 6 comprising reacting a compound of formula II



(II)


either with a compound of formula (IIIA)



(IIIA)

wherein the substituents are as defined any one of claims 1 to 6, in the presence of an activating agent ("method A")

or with a compound of formula (IIIB)



(IIIB)

wherein the substituents are as defined any one of claims 1 to 6 ; RG represents a reactive group (such as imidazolylcarbonyl), ("method B");


in each case optionally in the presence of a diluent and optionally in the presence of a reaction aid;

and optionally recovering the resulting compound of formula (I) in free form or in form of a salt;

and optionally converting a compound of the formula (I) obtainable according to method A or method B into a different compound of the formula (I), and/or converting an obtainable salt of a compound of the formula (I) into a different salt thereof, and/or converting an obtainable free compound of the formula (I) into a salt thereof, and/or separating an obtainable isomer of a compound of the formula (I) from one or more different obtainable isomers of the formula I.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. The compound (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({ 4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) of structure:



in free form or in pharmaceutically acceptable salt form.

2. The compound according to claim 1 in free form or in pharmaceutically acceptable salt form, for use as a pharmaceutical.

3. Use of the compound according to claim 1 in free form or in pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment of cancer.

4. Use according to claim 3 wherein the cancer is selected from sarcoma; lung; bronchus; prostate; breast (including sporadic breast cancers and sufferers of Cowden disease); pancreas; gastrointestinal cancer; colon; rectum; colon carcinoma; colorectal adenoma; thyroid; liver; intrahepatic bile duct; hepatocellular; adrenal gland; stomach; gastric; glioma; glioblastoma; endometrial; melanoma; kidney; renal pelvis; urinary bladder; uterine corpus; uterine cervix; vagina; ovary; multiple myeloma; esophagus; a leukaemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; a carcinoma of the brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma; melanoma; villous colon adenoma; a neoplasia; a neoplasia of epithelial character; lymphomas; a mammary carcinoma; basal cell carcinoma; squamous cell carcinoma; actinic keratosis; tumor diseases, including solid tumors; a tumor of the neck or head; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Walden stroem disease.

5. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 in free form or in pharmaceutically acceptable salt form and one or more pharmaceutically acceptable excipients.

6. A combined pharmaceutical composition, adapted for simultaneous or sequential administration, comprising a therapeutically effective amount of the compound according to claim 1 in free form of in pharmaceutically acceptable salt form and a therapeutically effective amount of one or more combination partners; and one or more pharmaceutically acceptable excipients.

7. A pharmaceutical composition according to claim 5 or a combined pharmaceutical composition according to claim 6 for the use in the treatment of cancer.

8. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

9. A compound according to claim 8 or a pharmaceutically acceptable salt thereof, for use in the treatment of a cancer selected from sarcoma; lung; bronchus; prostate; breast (including sporadic breast cancers and sufferers of Cowden disease); pancreas; gastrointestinal cancer; colon; rectum; colon carcinoma; colorectal adenoma; thyroid; liver; intrahepatic bile duct; hepatocellular; adrenal gland; stomach; gastric; glioma; glioblastoma; endometrial; melanoma; kidney; renal pelvis; urinary bladder; uterine corpus; uterine cervix; vagina; ovary; multiple myeloma; esophagus; a leukaemia;

acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; a carcinoma of the brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma; melanoma; villous colon adenoma; a neoplasia; a neoplasia of epithelial character; lymphomas; a mammary carcinoma; basal cell carcinoma; squamous cell carcinoma; actinic keratosis; tumor diseases, including solid tumors; a tumor of the neck or head; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Walden stroem disease.